nivolumab,ipilimumab
bms
['niche,(-niche 2),(-niche-2),(-niche2)', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)']
95% major path response for msih crc in #niche trial. amazing waterfall plot! #esmo22 
GI oncologist @SHEBA interests- pancreatic cancer, clinical trials